Fungal infections are one of the most significant causes of morbidity and mortality in immunocompromised patients. The incidence of invasive fungal infections, including those of the gastrointestinal tract, has increased significantly as numbers of immunocompromised patients have increased. The diagnosis of fungal infections in immunocompromised patients may be particularly problematic as these patients may present with atypical clinical features. Although Candida and Aspergillus species represent the majority of fungi diagnosed in the immunocompromised patient population, other fungi are emerging as increasingly common pathogens, and this review will focus on several important emerging fungal infections in immunocompromised patients.
*Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR
†Department of Pathology, Brigham and Women’s, Harvard Medical School, Boston, MA
All figures can be viewed online in color at http://www.anatomicpathology.com
D.A.M. is currently receiving grant funds for Malaria research from the NIH.
L.W.L. receives royalties from Amirsys Publishing Company for chapter royalties; D.A.M. has been paid money by Up To Date for malaria and stool diagnostics and has been paid money by Biosciences Solutions Group LLC as a partial owner of laboratory consulting firm. The remaining author has no conflicts of interest to disclose.
Reprints: Laura W. Lamps, MD, Department of Pathology, University of Arkansas for Medical Sciences, 4301 W. Markham Street, Slot 517, Little Rock, AR 72205 (e-mail: email@example.com).